George Simeon, CEO
George Simeon, CEO of Curevo and experienced business executive in the healthcare industry. Has worked globally with Novartis (Switzerland), J&J (Europe), SK Telecom (South Korea), GHX (Europe) and GS1 (USA & Europe). Advisor to early stage companies on growth strategies, strategic alliances, fundraising, and market entry.
Lisa Shelton, Associate Director Clinical Operations
Lisa Shelton, Associate Director of Clinical Operations and Licensed Adult Nurse Practitioner (ARNP). A successful leader in clinical trials investigation and study management in both sponsor and clinical site roles. Sponsor roles in clinical development and operations of first-in-human, phase 1 vaccine, and immunotherapy oncology studies. Experienced sub-investigator for first-in-human, and phase 1-3 trials in infectious disease vaccine and immunotherapy allergy trials.
Soobin Koh, Regulatory Affairs Manager
Soobin Koh, Regulatory Affairs Manager at Curevo. Global regulatory Affairs specialist with experience managing regulatory affairs from product development R&D to pre-market application.
Emma Fritzen, Program Manager
Emma Fritzen is the Program Manager for Curevo, and has proven experience developing and managing contracts, scope and budget in clinical operations. Emma also has experience with GMP and laboratory oversight, management of teams, and represents Clinical Operations in cross-functional initiatives.
Scientific Advisory Board Members
Steven Reed, PhD, Founder of the Infectious Disease Research Institute
Steve Reed is IDRI’s Founder and Curevo’s Executive Advisor and Director. His academic appointments include Professor of Medicine at Cornell University Medical College in New York and Research Professor of Pathobiology at the University of Washington. He serves on several editorial review committees, has served as a member of the Tropical Medicine Review Board of the National Institutes of Health, and has served as a member of diagnostic and vaccine steering committees of the World Health Organization. Steve’s research interests have focused on the immunology of intracellular infections, and on the development of vaccines and diagnostics for both cancer and infectious diseases.
Corey Casper, MD, MPH, CEO of the Infectious Disease Research Institute
Corey Casper serves as Curevo’s Project leader of CRV 101, CEO, and Chief Scientific Officer (CSO) at the Infectious Disease Research Institute (IDRI). Dr. Casper obtained an undergraduate degree in Biology from Wesleyan University, his MD from Cornell University Medical College. He completed a residency in Internal Medicine at University of California-San Francisco and a senior fellowship in infectious disease at the University of Washington, where he also received a Master of Public Health degree. Corey spent 17 years at the Fred Hutchinson Cancer Research Center and the University of Washington, where he remains a faculty member in Medicine and Global Health. Dr. Casper is an impactful scientist with nearly 100 peer-reviewed publications and a history of being the Principal Investigator of more than $15 million in peer-reviewed grant funding.
David Koelle, MD, University of Washington, Professor of Medicine, and Allergy and Infectious Disease
David Koelle, MD, is Professor in the Division of Allergy and Infectious Diseases at the University of Washington. His research focuses on the T cell immune response to viruses in the alphaherpesvirus family, including varicella zoster virus (VZV), the cause of shingles, as well as herpes simplex virus (HSV). Candidate HSV vaccines have been advanced through discovery, pre-clinical, and clinical stages of development. The laboratory also performs immune monitoring tests for specimens from vaccine clinical trials. Studies are sponsored by the US National Institutes of Health and by biotechnology and pharmaceutical companies. In addition to research, Dr. Koelle sees patients and assists with T cell-based diagnostic testing at the University of Washington.
Dr. Myron Levin, MD
Myron J. Levin, MD is a Professor of Pediatrics & Medicine at the University of Colorado School of Medicine (UCSOM) in the section of Pediatric Infectious Diseases and Epidemiology and is the Associate Director of the Pediatric HIV Clinic. He graduated from Harvard Medical School in 1960, and completed a residency in Internal Medicine at the Bronx Municipal hospital Center (Einstein Medical School). He spent the next three years at the National Institutes of Health; the last two years at NIH were devoted to research in molecular virology. He returned to Harvard in 1969 to complete a fellowship in Infectious Diseases, and remained as the first Chief of Infectious Diseases at the Sidney Farber Cancer Center (now the Dana-Farber Cancer Institute).
Dr. Soren Gantt
Dr. Gantt completed MD & PhD degrees at New York University, where he worked on malaria vaccine development. He then did Pediatrics Residency, Infectious Diseases Fellowship, and obtained an MPH degree, at University of Washington/Seattle Children’s Hospital, where he led studies of mother-child-transmission of HIV and human herpesviruses. Dr. Gantt is currently the Head of Pediatric Infectious Diseases at University of British Columbia and Director of Clinical Research at BC Children’s Hospital. His ongoing studies include finding the correlates of protection against CMV and EBV infections in children, conducting CMV and VZV vaccine trials, and chemotherapy trials for Kaposi sarcoma.